Piper Sandler on Sarepta Therapeutics (SRPT): 'SRPT Outperforms Revenue Guidance Driven By Elevidys'

Piper Sandler analyst Biren Amin reiterated an Overweight rating and $182.00 price target on Sarepta Therapeutics (NASDAQ: SRPT).

The analyst commented: "SRPT’s full-year 2024 total net product revenue of $1.79B (+56% yoy growth) beat both our estimate of $1.72B and cons of $1.71B, largely driven by Elevidys’ 4Q24 sales of $384M (+112% qoq growth) coming in above both our est ($324M) and cons ($328M). SRPT’s PMO franchise also saw modest growth from last quarter, with $254M in 4Q24 (+2.1% qoq growth; vs our estimate of $242M and cons of $245M). On SRPT’s LGMD portfolio, EMERGENE expression data for SRP-9003 in LGMD Type 2E are expected in 1H 2025, with potential BLA submission by YE-2025. SRPT also noted an upcoming R&D day (details TBD)."

For an analyst ratings summary and ratings history on Sarepta Therapeutics click here. For more ratings news on Sarepta Therapeutics click here.

Shares of Sarepta Therapeutics closed at $118.43 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Aurora Spine settles patent dispute, secures $600K insider loan
• Full Circle Lithium closes $5.14M private placement